$0.4021
-0.0049-1.2%
Last update: Nov 11, 9:02 AM
PharmaCyte Biotech Inc
PMCBNASDAQ
PharmaCyte Biotech fell 55.0% from $0.91 to $0.41, behind the S&P 500's +9.8%. Its worst day was May 15 (−15.4%), and its low came Oct 30 at $0.30.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
PharmaCyte Biotech shares rose 36.9%, while the S&P 500 rose 0.9%.
+36.9% · S&P 500 +0.9%
PharmaCyte Biotech closed at its highest level of the year, 34.8% above where the year started.
Story events cover the past 12 months · Times ET
+0.8% · S&P 500 +0.2%
EPS of $-1.24 was reported on $0.00 revenue.
+2.1% · S&P 500 +0.9%
EPS of $-0.17 was reported on $0.00 revenue.
−1.6% · S&P 500 +0.3%
PharmaCyte Biotech shares rose 17.1%, while the S&P 500 rose 0.8%.
+17.1% · S&P 500 +0.8%
EPS of $-0.36 was reported on $0.00 revenue.
−0.8% · S&P 500 −1.5%
EPS of $-0.54 was reported on $0.00 revenue.
−3.0% · S&P 500 −0.5%
PharmaCyte Biotech closed at its lowest level of the year, 66.6% below where the year started.
−9.0% · S&P 500 −1.8%
Where it ended: a close of $0.41 on Nov 9, 2026. Up next: Q2 2027 earnings on Dec 17, 2026.
Nothing in the past 12 months.
All PMCB analyst actionsNothing in the past 12 months.
All PMCB dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PMCB and SPY from Benzinga historical bars. Not investment advice.
